Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: Prediction of occurrence of leukopenia

Liver Transplantation

Volumn 14, Issue 8, 2008, Pages 1165-1173

  Hao, Chen ^a   Mao, Anwei ^a   Chen, Bing ^a   Shen, Baiyong ^a   Zhang, Weixia ^a   Shen, Chuan ^a   Chen, Erzhen ^a   Deng, Xiaxing ^a   Qiu, Weihua ^a   Yang, Weiping ^a   Peng, Chenghong ^a   Li, Hongwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ZENEPAX;

ABDOMINAL INFECTION; ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; DIARRHEA; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ROC CURVE;

EID: 49649087943     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21600     Document Type: Article

References (43)

1. Klupp J, Pfitzmann R, Langrehr JM, Neuhaus P. Indications of mycophenolate mofetil in liver transplantation. Transplantation 2005:80:S142-S146.
2. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005;1:505-526.
3. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266.
4. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003;25: 609-622.
5. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006;82:1004-1012.
6. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001;47:1241-1248.
7. Yamani MH, Starling RC, Goormastic M, Van Lente F, Smedira N, McCarthy P, et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000;69:2326-2330.
8. Cantin B, Giannetti N, Parekh H, Panchal SN, Kwok BW, Najem R, et al. Mycophenolic acid concentrations in longterm heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 2002;16:196-201.
9. Gajarski P.J, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am J Transplant 2004;4:1495-1500.
10. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001;23:305-315.
11. Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004:10:492-502.
12. Chen H, Peng CH, Yu ZC, Shen BY, Deng X, Qiu WH, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007;46:175-185.
13. An International Panel. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
14. Yu ZC, Cai WM, Xu D, Zhang WX, Chen B, Zhou PJ, et al. HPLC determination of mycophenolate mofetil and its active metabolite mycophenolic acid in human plasma. Chin J Pharm Anal 2005;25:381-384.
15. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
16. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988;46:631-644.
17. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62:920-926.
18. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-929.
19. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000;40: 624-633.
20. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-455.
21. Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther Drug Monit 2000;22:20-26.
22. Meiser BM, Pfeiffer M, Schmidt D, Reichenspurner H, Ueberfuhr P, Paulus D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18:143-149.
23. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001;47:88-94.
24. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004;75:434-447.
25. Premaud A, Rousseau A, Le Meur Y, Lachatre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004;26:609-619.
26. Schutz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30:1185-1187.
27. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 1999;31:1135-1137.
28. Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 1998;20:685-690.
29. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:759-768.
30. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998;65:1127-1129.
31. Lu YP, Lin B, Liang MZ, Nan F, Yu Q, Wang L, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in Chinese kidney transplant recipients treated with mycophenolate mofetfl.rransplant Proc 2004;36:2079-2081.
32. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil. combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1325.
33. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-663.
34. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-2386.
35. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajah A, et al. The impact of roycopbenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17:200-205.
36. Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000:40:527-532.
37. Hale MD, Nicholls AJ, Bullingham. RE, Hene R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-683.
38. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007;39:88-93.
39. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000;33:107-113.
40. Bailey MJ, Dickinson RG. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 2003;145:117-137.
41. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47.
42. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
43. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225-232.